{
"info": {
"nct_id": "NCT03947762",
"official_title": "Lanreotide 120 mg Effectiveness in Subjects With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice",
"inclusion_criteria": "* Subjects aged ≥ 18\n* Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months\n* Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation\n* Subject with Eastern Cooperative Oncology Group (ECOG) ≤2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Subject who is participating in an interventional study\n* Pregnant or breast-feeding women\n* Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "* Subjects aged ≥ 18",
"criterions": [
{
"exact_snippets": "aged ≥ 18",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "aged ≥ 18",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "* Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months",
"criterions": [
{
"exact_snippets": "diagnosed of functioning or non-functioning PanNET",
"criterion": "PanNET diagnosis",
"requirement": {
"requirement_type": "type",
"expected_value": [
"functioning",
"non-functioning"
]
}
},
{
"exact_snippets": "G1/ G2 (Ki67≤10%)",
"criterion": "tumor grade",
"requirement": {
"requirement_type": "grade",
"expected_value": [
"G1",
"G2"
]
}
},
{
"exact_snippets": "G1/ G2 (Ki67≤10%)",
"criterion": "tumor grade",
"requirement": {
"requirement_type": "Ki67 index",
"expected_value": {
"operator": "<=",
"value": 10,
"unit": "%"
}
}
},
{
"exact_snippets": "unresectable locally advanced tumour or metastatic disease",
"criterion": "tumor resectability and stage",
"requirement": {
"requirement_type": "resectability",
"expected_value": "unresectable"
}
},
{
"exact_snippets": "unresectable locally advanced tumour or metastatic disease",
"criterion": "tumor resectability and stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
},
{
"exact_snippets": "treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months",
"criterion": "lanreotide treatment duration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "months"
},
{
"operator": "<=",
"value": 12,
"unit": "months"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "diagnosed of functioning or non-functioning PanNET",
"criterion": "PanNET diagnosis",
"requirement": {
"requirement_type": "type",
"expected_value": [
"functioning",
"non-functioning"
]
}
},
{
"exact_snippets": "G1/ G2 (Ki67≤10%)",
"criterion": "tumor grade",
"requirement": {
"requirement_type": "grade",
"expected_value": [
"G1",
"G2"
]
}
}
]
},
{
"exact_snippets": "G1/ G2 (Ki67≤10%)",
"criterion": "tumor grade",
"requirement": {
"requirement_type": "Ki67 index",
"expected_value": {
"operator": "<=",
"value": 10,
"unit": "%"
}
}
}
]
},
{
"exact_snippets": "unresectable locally advanced tumour or metastatic disease",
"criterion": "tumor resectability and stage",
"requirement": {
"requirement_type": "resectability",
"expected_value": "unresectable"
}
}
]
},
{
"exact_snippets": "unresectable locally advanced tumour or metastatic disease",
"criterion": "tumor resectability and stage",
"requirement": {
"requirement_type": "stage",
"expected_value": [
"locally advanced",
"metastatic"
]
}
}
]
},
{
"exact_snippets": "treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months",
"criterion": "lanreotide treatment duration",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 3,
"unit": "months"
},
{
"operator": "<=",
"value": 12,
"unit": "months"
}
]
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* Subject who is participating in an interventional study",
"criterions": [
{
"exact_snippets": "Subject who is participating in an interventional study",
"criterion": "participation in an interventional study",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Subject who is participating in an interventional study",
"criterion": "participation in an interventional study",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "* Pregnant or breast-feeding women",
"criterions": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "breast-feeding",
"criterion": "breastfeeding",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Pregnant",
"criterion": "pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "breast-feeding",
"criterion": "breastfeeding",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "* Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours",
"criterions": [
{
"exact_snippets": "received any previous therapy for PanNET",
"criterion": "previous therapy for PanNET",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours",
"criterion": "short-acting octreotide subcutaneous (SC)",
"requirement": {
"requirement_type": "use",
"expected_value": "symptomatic control of functioning tumours"
}
}
]
},
"logical_structure": {
"condition": {
"and_criteria": [
{
"exact_snippets": "received any previous therapy for PanNET",
"criterion": "previous therapy for PanNET",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours",
"criterion": "short-acting octreotide subcutaneous (SC)",
"requirement": {
"requirement_type": "use",
"expected_value": "symptomatic control of functioning tumours"
}
}
]
},
"then_criteria": null,
"else_criteria": {
"exact_snippets": "received any previous therapy for PanNET",
"criterion": "previous therapy for PanNET",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation",
"criterions": [
{
"exact_snippets": "Subject not progressive at inclusion study visit according to investigator assessment",
"criterion": "disease progression",
"requirement": {
"requirement_type": "status",
"expected_value": "not progressive"
}
},
{
"exact_snippets": "using as a reference lanreotide initiation",
"criterion": "reference point for assessment",
"requirement": {
"requirement_type": "reference",
"expected_value": "lanreotide initiation"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "* Subject with Eastern Cooperative Oncology Group (ECOG) ≤2",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) ≤2",
"criterion": "ECOG performance status",
"requirement": {
"requirement_type": "performance status",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}